Daniel O’Day, chief executive officer of Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. He will provide support to ensure a smooth transition of activities until the end of February 2019. William Anderson, currently chief executive officer of Genentech, will succeed Mr. O’Day effective January 1, 2019. He will be based in Basel, reporting to Severin Schwan, Roche Group chief executive officer. He w...